Message #16 From:
NewsBot Date: July 7, 2006 07:28:00 AM
PBME News Pacific Biometrics to Present at 2006 C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
SEATTLE--(BUSINESS WIRE)--July 7, 2006--Pacific Biometrics, Inc. (OTCBB: PBME; PBI), a provider of specialty central laboratory services, has been selected as one of 125 featured companies to present at the 2006 C.E. Unterberg, Towbin Emerging Growth Opportunities Conference. PBI management will address attendees Tuesday, July 11, at 9:50 a.m. in the healthcare focus sector.
The annual conference, designed to facilitate maximum meeting opportunities between investors and emerging growth companies, is being held at New York City's Mandarin Oriental Hotel from Tuesday, July 11, through Wednesday, July 12. PBI will use this conference to educate investment professionals on the Company's core competence in specialty laboratory services, its wholly owned technology subsidiary PBI Technology, Inc., and its plans for future growth. After successful completion of a recent financing, PBI currently expects it is sufficiently capitalized to fund operations through the fourth quarter of fiscal 2008, and the Company does not anticipate a need for additional near-term financing for its core operations. As reported in recent filings, the Company will continue to seek opportunities to capitalize PBI Technology, as well as explore strategic opportunities for the core business, including acquisitions.
Members of the financial and investment community, the media and other interested parties may listen to the live Web cast of PBI's presentation by accessing the link, (http://www.wsw.com/webcast/ceut4/pbme/). The presentation will be archived on the "Investors" section of PBI's corporate Web site for 90 days following the conference.
Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, and through its non-profit affiliate Pacific Biometrics Research Foundation, is one of only three U.S.-based members of the Centers for Disease Control (CDC) Cholesterol Reference Method Laboratory Network. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies.
Pacific Biometrics, through its wholly owned subsidiary PBI Technology, also owns several patented and patent-pending technologies, including monitoring devices for glucose and changes in bone turnover, an advanced, proprietary, isothermal DNA amplification technology, and a gene-based cell viability technology to distinguish live from dead cells in a broad range of diagnostic applications.
For more information about Pacific Biometrics, visit the company's web site at www.pacbio.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release includes forward-looking statements including, but not limited to, our strategic planning and business development plans, our financial results, our future growth, our capital requirements, and the viability and acceptance of our products and services in the market. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, our ability to bid on and win laboratory services contracts, the success of our marketing and business development efforts, competition in the industry, and our ability to manage growth, as well as the risks and other factors set forth in our periodic filings with the U.S. Securities and Exchange Commission (including our Form 10-KSB for the year ended June 30, 2005 and our Forms 10-QSB for the quarters ended September 30, 2005, December 31, 2005, and March 31, 2006).
